摘要
结直肠癌是全球最常见的恶性肿瘤之一,尤其转移性结直肠癌(metastatic colorectal cancer,mCRC)预后较差。人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)作为mCRC新兴的生物标志物近年来备受瞩目,本文就HER2阳性mCRC靶向治疗研究进展做一综述,为结直肠癌的诊断、治疗及预后提供参考。
Colorectal cancer(CRC)is one of the most common cancers worldwide,especially metastatic colorectal cancer(mCRC)which has a poor prognosis.Human epidermal growth factor receptor 2(HER2),as an emerging biomarker of mCRC,has attracted much attention in recent years.This paper reviews the research progress of targeted therapy for HER2-positive metastatic colorectal cancer to provide evidence for diagnosis,treatment and prognosis of CRC.
作者
李雨晴
胡静
钱晓萍
Li Yuqing;Hu Jing;Qian Xiaoping(Nanjing Drum Tower Hospital,School of Medical,Southeast University,Nanjing 210008,Jiangsu,China;Cancer Center,Nanjing Drum Tower Hospital(i.e.the Affiliated Hospital of Nanjing University Medical School),Nanjing 210008,Jiangsu,China)
出处
《肿瘤预防与治疗》
2024年第7期618-623,共6页
Journal of Cancer Control And Treatment
基金
江苏省自然科学基金面上项目(编号:BK20211007)
江苏省中医药科技发展重点项目(编号:ZD202227)
南京市医学重点基金(编号:ZKX21028)。
